Potassium Sulfate
drugOn this page
Also known as Arcanum duplicatumE-515(I)INS NO.515(I)INS-515(I)Kali sulphuricumPot sulfPotassium (as sulfate)Potassium sulfate component of bli-801Potassium sulfate component of bli801Potassium sulfate component of suclearSal polychrestumSulfuric aciddipotassium saltTartarus vitriolatus
Summary
Potassium Sulfate (CHEMBL2021424) is an approved small molecule.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Clinical trials: 1
- Chemistry: 174.26 Da · K2O4S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2021424 |
| Name | Potassium Sulfate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 24507 |
| ChEBI | CHEBI:32036 |
| Molecular formula | K2O4S |
| Molecular weight | 174.26 |
| InChIKey | OTYBMLCTZGSZBG-UHFFFAOYSA-L |
SMILES: [O-]S(=O)(=O)[O-].[K+].[K+]
IUPAC name: dipotassium;sulfate
Also known as: Arcanum duplicatum, E-515(I), INS NO.515(I), INS-515(I), Kali sulphuricum, Pot sulf, Potassium (as sulfate), Potassium sulfate, Potassium sulfate component of bli-801, Potassium sulfate component of bli801, Potassium sulfate component of suclear, Sal polychrestum
Patent coverage: 61,106 distinct patent families (112,462 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02523911 | Not specified | WITHDRAWN | Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.